TCR2 Therapeutics Inc (TCRR)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

100 BINNEY STREET CAMBRIDGE, MA 02142

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuCĀ®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

Data as of 2021-08-02 09:05:17 -0400
Market Cap474.741 Million Shares Outstanding38.162 Million Avg 30-day Volume304.487 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.52758 52-week High/Low35.86 / 12.15 Next Earnings Date2021-08-11 Price to Cash FLow (P/CF) -29.097
Data provided by IEX Cloud
View SEC Filings from TCRR instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 3 -33.33% 2 (0.12%) 3 (0.17%) -33.33%
Funds Holding: 127 119 6.72% 46 (2.7%) 44 (2.55%) 4.55%
13F shares: 37.66 Million 32.887 Million 14.51% 26.062 Million 23.591 Million 10.47%
% Ownership 98.749 98.3988 0.36% 68.3368 70.5864 -3.19%
New Positions: 22 44 -50.0% 5 16 -68.75%
Increased Positions 59 41 43.9% 18 13 38.46%
Closed Positions 14 8 75.0% 3 5 -40.0%
Reduced Positions 30 18 66.67% 19 8 137.5%
Total Calls 85.319 Thousand 122.514 Thousand -30.36% 0 31 Thousand -100.0%
Total Puts 118.524 Thousand 113.636 Thousand 4.3% 43.4 Thousand 37.5 Thousand 15.73%
PUT/CALL Ratio 1.39 0.93 49.46% 1.21 14.88%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TCRR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TCRR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

OLAGUNJU PETER CHIEF TECHNICAL OFFICER

  • Officer
2,192 2021-07-26 2

JUSTICE ANGELA CHIEF PEOPLE OFFICER

  • Officer
200,326 2021-04-02 3

TOMASELLO SHAWN

  • Director
0 2021-02-03 2

HOFMEISTER ROBERT CHIEF SCIENTIFIC OFFICER

  • Officer
45,850 2020-12-22 4

SOMAIYA MAYUR IAN CHIEF FINANCIAL OFFICER

  • Officer
1,473 2020-12-14 3

BAEUERLE PATRICK

  • Director
350,786 2020-12-10 1

GIBSON NEIL W

  • Director
0 2020-12-10 1

ALLEN ANDREW R

  • Director
0 2020-12-10 1

CARDAMA ALFONSO QUINTAS CHIEF MEDICAL OFFICER

  • Officer
1,925 2020-12-10 2

MENZEL GARRY E PRESIDENT AND CEO

  • Officer
  • Director
86,794 2020-12-10 2

HOOS AXEL

  • Director
0 2020-12-10 1

WEBSTER STEPHEN W

  • Director
0 2020-12-10 1

JOVAN-EMBIRICOS MORANA

GLOBEWAYS HOLDINGS LTD

GLOBEWAYS HOLDINGS II LTD

F2 CAPITAL I 2015 LTD

F2 CAPTIAL I 2017 LTD

F2 MG LTD

F2 BIOSCIENCE II 2017 LTD

F2 - TPO INVESTMENTS LLC

F2 BBG LLC

F2 CAPITAL I 2019, LLC

  • 10% Owner
2,518,056 2019-12-18 0

JOVAN-EMBIRICOS MORANA

GLOBEWAYS HOLDINGS LTD

GLOBEWAYS HOLDINGS II LTD

F2 CAPITAL I 2015 LTD

F2 CAPTIAL I 2017 LTD

F2 MG LTD

F2 - TPO INVESTMENTS LLC

  • 10% Owner
7,803,932 2019-12-09 0

JOVAN-EMBIRICOS MORANA

GLOBEWAYS HOLDINGS LTD

GLOBEWAYS HOLDINGS II LTD

F2 CAPITAL I 2015 LTD

F2 CAPTIAL I 2017 LTD

F2 MG LTD

F2 - TPO INVESTMENTS LLC

F2 BBG LLC

F2 CAPITAL I 2019, LLC

  • 10% Owner
5,999,191 2019-09-20 0

JOVAN-EMBIRICOS MORANA

GLOBEWAYS HOLDINGS II LTD

F2 CAPITAL I 2019, LLC

  • 10% Owner
3,507,157 2019-08-21 0

UBS ONCOLOGY IMPACT FUND L.P.

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

MPM ONCOLOGY IMPACT MANAGEMENT LP

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC

  • 10% Owner
3,370,982 2019-02-19 0

MPM SUNSTATES FUND, L.P.

MPM ASSET MANAGEMENT INVESTORS SUNSTATES FUND LLC

MPM SUNSTATES FUND GP LLC

MPM SUNSTATES GP MANAGING MEMBER LLC

  • 10% Owner
4,050,865 2019-02-19 0

MPM BIOVENTURES 2014, L.P.

FOLEY TODD

EVNIN LUKE

MPM BIOVENTURES 2014 (B), L.P.

MPM ASSET MANAGEMENT INVESTORS BV2014 LLC

MPM BIOVENTURES 2014 LLC

MPM BIOVENTURES 2014 GP LLC

MPM ASSET MANAGEMENT LLC

  • 10% Owner
4,050,865 2019-02-19 0

UPNORTH INVESTMENT LTD

CHINA MOLYBDENUM CO., LTD.

CHINA MOLYBDENUM (HONG KONG) CO LTD

  • 10% Owner
No longer subject to file 2019-02-19 0

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
No longer subject to file 2019-02-19 0

GADICKE ANSBERT

  • Director
  • 10% Owner
12,669,018 2019-02-19 0

FINER MITCHELL H.

  • Director
36,731 2019-02-13 0

JOVAN-EMBIRICOS MORANA

GLOBEWAYS HOLDINGS LTD

F2 CAPITAL I 2015 LTD

F2 BIOSCIENCE II 2017 LTD

F2 CAPTIAL I 2017 LTD

F2 MG LTD

F2 - TPO INVESTMENTS LLC

  • Director
  • 10% Owner
0 2019-02-13 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

OLAGUNJU PETER - Officer CHIEF TECHNICAL OFFICER

2021-07-27 17:19:14 -0400 2021-07-26 A 286,367 a 286,367 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
TCR2 THERAPEUTICS INC TCRR 2021-08-05 22:15:04 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 21:45:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 21:15:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 20:45:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 20:15:04 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 19:45:04 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 19:15:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 18:45:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 18:15:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 17:45:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 17:15:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 16:45:02 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 16:15:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 15:45:03 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 15:15:02 UTC -0.3065 0.3865 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 14:45:02 UTC -0.171 0.251 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 14:15:04 UTC -0.171 0.251 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 13:45:04 UTC -0.171 0.251 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 13:15:03 UTC -0.171 0.251 350000
TCR2 THERAPEUTICS INC TCRR 2021-08-05 12:45:03 UTC -0.171 0.251 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments